HMC-1 cells containing common KIT variants, isolated from a patient with mast cell leukemia (12), remain one of the most frequent preclinical models to test the efficacy of drugs targeting oncogenic KIT activity and to predict signaling pathways and behavior of neoplastic mast cells (15). The gene discussed is KIT; the disease is mast cell leukemia.